

2015-2019 US Hospital Tumor Marker Testing Market Forecasts and Emerging Opportunities for Suppliers - Competitive Landscape, Supplier Shares by Test, Innovative Technologies, Instrumentation Review

https://marketpublishers.com/r/203D7090181EN.html

Date: July 2015

Pages: 567

Price: US\$ 5,200.00 (Single User License)

ID: 203D7090181EN

Abstracts

This new report from VPGMarketResearch.com contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in US hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.



Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 567 pages and 50 tables



Contents

INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Brest Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)



- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
 - **ADA**
 - **B-Protein**
 - **PNP**
 - 5'-Nucleotidase
- 27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - **CD44**
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src
- 28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - **ECFR**



Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18



DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opiod Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

C. Instrumentation Review And Market Needs

- 1. Abbott AxSYM
- 2. Abbott Architect c4000
- 3. Abbott Architect i2000 Series
- 4. Abbott Architect ci8200 System
- 5. Beckman Coulter UniCel Series
- 6. Beckman Coulter Access
- 7. Binding Site ESP600
- 8. bioMerieux Mini Vidas



- 9. Carolina Chemistries BioLis 24i
- 10. DiaSorin Liaison
- 11. Horiba ABX Pentra
- 12. Inverness DS2
- 13. J&J Vitros ECi/ECiQ
- 14. J&J Vitros 3600
- 15. J&J Vitros 5600
- 16. Olympus AU5400
- 17. Olympus AU3000i
- 18. Olympus AU2700
- 19. Roche Modular Analytics
- 20. Roche Cobas Integra
- 21. Roche Cobas Integra 400 Plus
- 22. Roche Elecsys
- 23. Roche Cobas c311
- 24. Siemens ADVIA Centaur
- 25. Siemens Dimension
- 26. Siemens Dimension RxL Max
- 27. Siemens Dimension Vista
- 28. Siemens Immulite
- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy
- D. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence



- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- i. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
- b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

- 3 SR, and others
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- E. Personal Testing



U.S.A.

- A. Executive Summary
- **B.** Business Environment
 - 1. Health Care Expenditures
 - 2. Cost Consciousness
 - 3. Industry Consolidation
 - 4. Managed Care
 - 5. Hospitals
 - 6. Admissions
 - 7. Length of Stay
 - 8. Industry Diversification
 - 9. Physician Demographics
 - 10. Population Aging
 - a. Chronic Illness
 - b. Disease Incidence
 - c. Susceptibility to latrogenesis
 - d. Multiple Illness Cases
 - 11. Laboratory Regulations
- C. Market Structure
 - 1. Centralized Testing
 - a. Hospitals
 - b. Commercial/Private Laboratories
 - 2. POT/Decentralized Testing
 - a. Physician Offices/Group Practices
 - b. Cancer Clinics
 - c. Point-Of-Care Testing
 - d. Other Decentralized Testing Locations
- D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS



ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- **B.** Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott

AdnaGen

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid



Correlogic Systems/Vermillion

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Otho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Thermo Fisher

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zila/Alere



Arca

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

Kreatech

Kyowa Medex

Life Technologies

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

Otho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion



Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE

Zila



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates Per 100,000 Population

U.S., Laboratories Performing Cancer Diagnostic Tests

U.S., Hospital Laboratories Performing Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test



- U.S., Total Cancer Diagnostics Sales By Major Supplier
- U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
- U.S., AFP Testing Market Diagnostics Sales by Major Supplier
- U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
- U.S., CEA Testing Market Diagnostics Sales by Major Supplier
- U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
- U.S., HCG Testing Market Diagnostics Sales by Major Supplier
- U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
- U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
- U.S., PAP Testing Market Diagnostics Sales by Major Supplier
- U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
- U.S., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2015-2019 US Hospital Tumor Marker Testing Market Forecasts and Emerging

Opportunities for Suppliers - Competitive Landscape, Supplier Shares by Test, Innovative

Technologies, Instrumentation Review

Product link: https://marketpublishers.com/r/203D7090181EN.html

Price: US\$ 5,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/203D7090181EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970